Vitamin K Inhibitors
1 drugsAbout Vitamin K
Vitamin K is a group of fat-soluble vitamins essential for blood coagulation, bone metabolism, and cell growth regulation. It acts as a cofactor for gamma-glutamyl carboxylase, modifying clotting factors and influencing other biological processes.
Vitamin K's established physiological importance suggests that modulating its activity could offer therapeutic benefits. Currently, there is no genetic evidence directly linking Vitamin K variations to disease susceptibility.
There is one FDA-approved drug, VITAMIN K1 (Pfizer), a small molecule indicated in immunology. VITAMIN K1 was first approved in 1983 and has 10 indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Osteo Arthritis Knee with only 1 trials.
Top Vitamin K Drugs
The competitive landscape is highly concentrated, with Pfizer holding the only approved drug.
The lack of competitors presents an opportunity for new entrants, but also indicates potential market challenges.
Vitamin K Clinical Trials 17 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 6 | 0 | 1 | 100% |
| Phase 2 | 3 | 3 | 0 | 0 | 100% |
| Phase 3 | 3 | 1 | 1 | 1 | 50% |
| Phase 4 | 4 | 3 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (14 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 15 clinical trials targeting Vitamin K.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities